Allovir Inc
Change company Symbol lookup
Select an option...
ALVR Allovir Inc
PETV PetVivo Holdings Inc
HOPE Hope Bancorp Inc
FNKO Funko Inc
AFTPF AFT Pharmaceuticals Ltd
AIMD Ainos Inc
NG NovaGold Resources Inc
KRNLW Kernel Group Holdings Equity Warrants Exp 02 Feb 2026 *W EXP 02/02/2026
BRKHW BurTech Acquisition Equity Warrants Exp 18th Dec 2026 *W EXP 12/18/2026
UHALB Amerco
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Closing Price
$7.24
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Average)
Volume:
194,215

10-day average volume:
190,062
194,215

Display:

Providers:

UpdateCancel
6 providers
November 15, 2022
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare...(BusinessWire)

November 03, 2022
Final Data from AlloVir's Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses...(BusinessWire)

AlloVir Reports Third Quarter 2022 Financial Results

--Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention Study by Year-End --Company to Host Investor Webcast on December 14 with Clinical Trial Investigators on Posoleucel for Prevention of Viral Infections in Patients Following...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.